If Opioid REMS Mandates Prescriber Training, Firms May Ask DEA For Help
Executive Summary
If FDA decides to incorporate mandatory prescriber training into a Risk Evaluation and Mitigation Strategy for extended-release opioids, industry implementation options include setting up an industry-wide registry or seeking congressional action to tie training verification into a Drug Enforcement Administration registry
You may also be interested in...
Purdue Seeks Equity In Abuse/Misuse Labeling For Immediate-Release Opioids
The manufacturer of extended-release oxycodone contends in a citizen petition that immediate-release and extended-release/long-acting opioid analgesics contain the same active ingredients and pose a similar risk of abuse, misuse and overdose.
FDA's CME Expectations For Opioid Prescribers Keep Sponsors At A Distance
Manufacturers of long-acting/extended-release opioids must develop a blueprint for physician education in pain management with their products, but otherwise will be involved only at arms’ length in the doctor training portion of the Risk Evaluation and Mitigation Strategies.
FDA's CME Expectations For Opioid Prescribers Keep Sponsors At A Distance
Manufacturers of long-acting/extended-release opioids must develop a blueprint for physician education in pain management with their products, but otherwise will be involved only at arms’ length in the doctor training portion of the Risk Evaluation and Mitigation Strategies.